Spondyloarthropathies News

WASHINGTON — According to findings presented at the American College of Rheumatology Annual Meeting, 75% of patients with peripheral spondyloarthritis treated with golimumab experienced clinical remission.

WASHINGTON — Patients with ankylosing spondyloarthritis, psoriatic arthritis and spondyloarthropathies who were treated with tumor necrosis factor inhibitors were seven-times more likely to develop tuberculosis than the general population, according to findings presented at the American College of Rheumatology Annual Meeting.

WASHINGTON — According to data presented at the American College of Rheumatology Annual Meeting, NSAIDs and tumor necrosis factor inhibitors may have a synergistic effect in slowing radiographic progression of ankylosing spondylitis.

WASHINGTON — Statin use was associated with a 32% reduction in mortality in a large cohort of patients with ankylosing spondylitis and psoriatic arthritis, according to findings presented at the American College of Rheumatology Annual Meeting.

For patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis, the 5-year safety data of 50-mg and 100-mg golimumab remained consistent with its 3-year results, according to a recently published study.

Although there was radiographic spinal progression, spinal mobility and physical function were consistent in patients with ankylosing spondylitis who were treated with up to 10 years of anti-tumor necrosis factor-alpha inhibitors, according to a recently published study.

Following a positive opinion by a European Medicine Agency committee, the certolizumab pegol autoclicks prefilled pen is now available on the United Kingdom’s National Health Service, according to a UCB press release.

Adults with atopic dermatitis had a higher susceptibility of autoimmune diseases compared with controls, with a significantly higher occurrence in smokers, according to recently published results of a population-based study.

The Cover Story of this issue of Healio Rheumatology examines advances in the field of interleukin-6 biology and clinical medicine. It has been more than 30 years since investigators at Osaka University discovered and cloned interleukin-6 and its receptor, and more than 6 years since tocilizumab, an antibody against that receptor, was approved in the United States for the treatment of rheumatoid arthritis.

The interleukin-6 pathway has been on the radar of the rheumatology community as an important marker and a target for therapy, perhaps most notably since the FDA approval of tocilizumab for rheumatoid arthritis in 2010. A number of agents with activity in the pathway are close to market or are in the pipeline.